09877 健世科技－Ｂ
JENSCARE - B
JENSCARE - B
| Listing Date | 2022/10/10 |
| Listing Price | 27.800 |
Subscription Result
- Subscription Rate1.52x
- Guarantee One Lot Size2 lot
- One Lot Success Rate58.01%
|
|
|
|
|
|
|
|
|
|
IPO Detail
COMPANY PROFILE
Jenscare Scientific Co. is a China-based medical device company dedicated to the development of interventional products for the treatment of structural heart diseases. It has developed a series of treatment solutions targeting different types of structural heart diseases, including tricuspid valve diseases, aortic valve diseases, mitral valve diseases and heart failure.
LuX-Valve, its Core Product and its proprietary first-generation transcatheter tricuspid valve replacement (“TTVR”) system, is designed for patients with both severe tricuspid regurgitation and high surgical risk. It is expected to submit the trial results for NMPA approval in the fourth quarter of 2022 and obtain the NMPA approval for the commercialization of LuX-Valve in the second half of 2023.
Ken-Valve, its another Core Product, is designed for the treatment of severe aortic regurgitation (or combined with aortic stenosis). It is expected to obtain the NMPA approval for the commercialization of Ken-Valve in the first half of 2024.
As at September 13, 2022, the Group product pipeline included ten product candidates. it had 143 issued patents and 160 patent applications in more than 10 countries or regions, including China, the United States, Europe, Brazil, and Canada.
BASIC INFORMATION
| Market | Hong Kong (Main Board) |
| Business Nature | Health Care |
| Major Business Area | China |
| Board Lot | 200 |
GLOBAL OFFERING
| No. of Offer Shares | 8.08M H shares |
| No. of International Offer Shares | 7.27M H shares |
| No. of HK Offer Shares | 0.81M H shares |
| Offer Price | $26.70 - $28.80 |
| Stock Code | 9877 |
| Sponsor(s) | Citigroup Global Markets Asia Limited, China International Capital Corporation Hong Kong Securities Limited |
| Underwriter(s) | China International Capital Corporation Hong Kong Securities Limited, Citigroup Global Markets Asia Limited, Huatai Financial Holdings (Hong Kong) Limited, ABCI Securities Company Limited, BOCOM International Securities Limited, Futu Securities International (Hong Kong) Limited, Tiger Brokers (HK) Global Limited, Silverbricks Securities Company Limited |
TIME TABLE
| Application Period | Sep 23 (Fri) - noon, Sep 29 (Thu) |
| Price Determination Date | Sep 29 (Thu) |
| Result Announcement Date | On or before Oct 07 (Fri) |
| Result Announcement Date | On or before Oct 07 (Fri) |
| Dealings in Shares commence on | Oct 10, 2022. (Mon) |
Reallocation of Shares Offered
| Times of HK Offer Shares Subscription | 15X - 50X | 50X - 100X | Over 100X |
| % of total shares reallocated to HK Offer | 30% | 40% | 50% |
Sales Statistics (HKD)
| Offer Price | $26.70 - $28.80 |
| Capitalization | 11.14B - 12.01B |
| NAV / share ($) | $3.91 - $3.95 (Unaudited pro forma adj NAV / share) |
Use Of Proceeds
| Assuming the offer price being at HKD 27.75, the net proceeds raised would be HKD 154.40M, of which |
| 65% : Research and development, manufacturing and commercialization of Core Products, namely, LuX-Valve and Ken-Valve |
| 25% : Research and development, clinical trials and product registration of other product candidates in pipeline, including LuX-Valve Plus, KenFlex and mitral valve products |
| 10% : Working capital |
IPO NEWS
| 10/10/2022 16:08 |
| {New Stock}JENSCARE-B(09877) ends up 1.62% at HK$28.25 |
| 10/10/2022 09:20 |
| {New Stock}JENSCARE-B(09877) opens up 0.72% at HK$28 |
| 07/10/2022 18:35 |
| {New Stock}JENSCARE - B(09877) ends up 0.72% on grey market |
Related Document
| Prospectus |  Chinese Version | English Version |
| Remark： | The above information is referenced from the prospectus. |
| All data is calculated from the non- exercise rights(if applicable). |
Name︰
--
--
--
Subscription --
Result Announcement --
Listing --Offer Price︰--
| Currency | : |
| Listing Price | : |
| Board Lot | : |
| Admission Fee* |
: |
| Subscribing Lot | : |
| Subscribing Fee | : |
| Subscribing Amount | : |
*Admission fees include brokerage of 1%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.005% and FRC transaction levy of 0.00015% (i.e. 1.0077% in total).